THOUSAND OAKS, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Amgen today announced that new data will be presented on the burden of osteoporosis, current osteoporosis treatment challenges and Prolia(TM) (denosumab) at the 2009 American Society for Bone and Mineral Research (ASBMR) annual meeting in Denver from Sept. 11-15, 2009. Prolia currently is being evaluated by regulatory bodies in the United States (U.S.), the European Union, Switzerland, Australia and Canada as a potential therapy for postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation for prostate and breast cancer.
ASBMR abstracts are available and can be viewed online at www.asbmr.org. Identified below are selected abstracts of interest on Amgen research.
-- Effects of Denosumab on Bone Histomorphometry: the FREEDOM and STAND Studies Lead Author: Reid IR
Abstract No. 1027 (Saturday, Sept. 12, 2009, 10:30am MT)
-- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass
Lead Author: Bone H
Abstract No. 1243 (Monday, Sept. 14, 2009, 5:30pm MT)
-- Evaluation of Health-Related Quality of Life in Postmenopausal Women Who Participated in the FREEDOM Trial
Lead Author: Siris E
Abstract No. 1282 (Tuesday, Sept. 15, 2009, 11:15am MT)
-- Impact of Adherence to Osteoporosis Medication on Risk of Fracture
Lead Author: Halpern R.
Abstract No. SA0368 (Saturday, Sept. 12, 2009, 11:30 am MT)
-- Comorbidities, Bone Loss and Concomitant Medication Use in European Postmenopausal Women: POSSIBLE EU
Lead Author: Freemantle N
Abstract No. MO0369 (Monday, Sept. 14, 2009, 12:00pm MT)
About Prolia(TM) (denosumab)
Prolia is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone). Prolia is being investigated for its potential to inhibit all stages of osteoclast activity through a targeted mechanism. Prolia is being studied in a range of bone loss conditions including postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation for prostate and breast cancer.
Amgen has also submitted marketing applications for use of Prolia in the European Union, Canada, Switzerland, and Australia.
The economic burden of osteoporosis is comparable to that of other major chronic diseases; for example, in the U.S., the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma.(i,ii,iii) It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer.(iv)
Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 9, 2009 and expressly disclaims any duty to update information contained in this news release.
In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.
i. Burge R, et al. J Bone Miner Res. 2007; 22:465-475
iii. "Economic Cost of Cardiovascular Diseases." American Heart Association. Accessed on February 24, 2009 at http://www.americanheart.org/statistics/10econom.html.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)
SOURCE Amgen
CONTACT: U.S. Media, Sarah Reines: +1-805-447-9783, Investors, Arvind
Sood, +1-805-447-1060, both of Amgen, Thousand Oaks
Web site: http://www.amgen.com/
